Rituximab in ANCA-associated vasculitis: fad or fact?
نویسنده
چکیده
A number of case reports and case series of patients with Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome have supported the use of rituximab (RTX) for the treatment of refractory ANCA-associated vasculitis (AAV). Whether B cell depletion with RTX could replace cyclophosphamide as a first-line therapy for patients with severe AAV remains to be proven. Two studies, recently published in the New England Journal of Medicine, have examined the efficacy of RTX in inducing remission in patients with severe AAV.
منابع مشابه
Rituximab in ANCA-Associated Vasculitis: Fad or Fact?
A number of case reports and case series of patients with Wegener’s granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome have supported the use of rituximab (RTX) for the treatment of refractory ANCA-associated vasculitis (AAV). Whether B cell depletion with RTX could replace cyclophosphamide as a first-line therapy for patients with severe AAV remains to be proven. Two studies, ...
متن کاملRituximab in ANCA-Associated Vasculitis: Fad or Fact?
A number of case reports and case series of patients with Wegener’s granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome have supported the use of rituximab (RTX) for the treatment of refractory ANCA-associated vasculitis (AAV). Whether B cell depletion with RTX could replace cyclophosphamide as a first-line therapy for patients with severe AAV remains to be proven. Two studies, ...
متن کاملRituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.
BACKGROUND B-cell depletion with rituximab, a chimeric anti-CD20 antibody, is a novel treatment for refractory and relapsing ANCA-associated small-vessel vasculitis. Data are limited and most reports describe single patients or small numbers of patients followed prospectively. METHODS We report a single-centre experience with 15 patients who received rituximab for refractory or relapsing ANCA...
متن کاملRituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: single centre experience with 15 patients
Background. B-cell depletion with rituximab, a chimeric anti-CD20 antibody, is a novel treatment for refractory and relapsing ANCA-associated small-vessel vasculitis. Data are limited and most reports describe single patients or small numbers of patients followed prospectively. Methods. We report a single-centre experience with 15 patients who received rituximab for refractory or relapsing ANCA...
متن کاملRituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
BACKGROUND The combination of cyclophosphamide and glucocorticoids leads to remission in most patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides. However, even when patients receive maintenance treatment with azathioprine or methotrexate, the relapse rate remains high. Rituximab may help to maintain remission. METHODS Patients with newly diagnosed or relapsing gran...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Nephron. Clinical practice
دوره 118 2 شماره
صفحات -
تاریخ انتشار 2011